Bavarian Nordic commences Phase II combination trial for prostate cancer

Danish-based biotechnology firm Bavarian Nordic has commenced a Phase II clinical trial of Prostvac (rilimogene) in combination with Yervoy (ipilimumab) and / or Opdivo (nivolumab) to treat localised prostate cancer patients.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news